Analyst Color

Fortinet Targets 45% Growth-Margin Combo, $450 Million Refresh Boost: Analysts See Big Upside
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?

Analyst Color Recent News

Warner Bros. Discovery NBA Deal 'Best Case Scenario': Analyst Says Renewal Structure Could Boost Annual Profit
Warner Bros. Discovery reaching a deal with the NBA that includes some international rights and licensing of "Inside the NBA" could be a win.
Snowflake 'One Of The Most Compelling Stories In Software' Ahead Of Earnings: Analyst
Analyst expects strong performance from big names ahead of Q3 earnings. Palo Alto Networks, Couchbase, and Snowflake remain top picks.
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies.
Vertiv's Earnings Estimates Raised By Analyst Amid Improved Margin Outlook
Vertiv's earnings estimates are raised by BofA analyst due to stronger revenue growth and improved margin outlook.
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones
Analysts initiated coverage on Septerna, Inc. with Overweight ratings and price targets of $50 and $38. SEPN's innovative platform and potential pipeline make it a promising biopharma player.
Bitdeer Technologies' Strong Growth Potential Highlighted By Analysts Amid Bitcoin Bull Market
Analysts remain bullish on Bitdeer Technologies, highlighting strong growth potential amid the Bitcoin bull market, despite a dip in Q3 revenue.
Joby Aviation Positioned For Air Taxi Leadership, Thanks To FAA Backing And Uber Partnership: Analyst
Analyst initiates coverage on JOBY with Buy rating and $8 price target. JOBY's partnership with Uber and focus on software position them well in air taxi market.
Walmart's Q3 Performance Shows Structural Gains Fueling Future Growth: Analyst
JP Morgan analyst views Walmart's strong Q3 results, with sales of $169.6B and raised guidance for EPS and sales growth.
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
Incyte pauses MRGPRX2 study enrollment due to toxicology concerns, with analysts calling the update disappointing amid pipeline reevaluations.
Nvidia Q3 Earnings Preview: Analysts Expect 'Beat-N-Raise On Continued Data Center Strength'
Nvidia analysts have short-term concerns on supply constraints, but long-term demand outlook is strong and not slowing down.
Why BlackRock's Rick Rieder Believes Markets Will Rise Despite Valuation Worries
Rieder emphasized that despite the allure of money-market funds due to high interest rates, the momentum in stock buying remains robust.
Jim Cramer Weighs In As Apple Slips While Nasdaq Climbs: 'I Would Wait For A Dip Because The Bears Are All Over It… "
His comments come at a time when Apple shares are under pressure despite the Nasdaq index, known for its tech-heavy composition, experiencing gains.
Tesla China's Weekly Insurance Registrations Points Towards Strong Q4 In Key Market
Tesla China sales are picking up momentum despite trailing behind Chinese EV maker BYD.
Jim Cramer Thinks Trump's Plans For Robotaxis Are 'Fanciful,' But He Is Still Bullish On Tesla Stock: 'The Musk Premium Will Work Its Magic In Other Ways'
Jim Cramer believes reports of Trump possibly relaxing autonomous driving regulations is a bad reason to own Tesla stock, but still supports buying.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

©2024Benzinga | All Rights Reserved